Fluticasone furoate: Once-daily evening treatment versus twice-daily treatment in moderate asthma

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Woodcock, Ashley ^a   Bleecker, Eugene R ^b   Busse, William W ^c   Lötvall, Jan ^d   Snowise, Neil G ^e   Frith, Lucy ^e   Jacques, Loretta ^e   Haumann, Brett ^e   Bateman, Eric D ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Asthma; Efficacy; Fluticasone furoate; Inhaled corticosteroid; Once daily; Safety

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PLACEBO; ANDROSTANE DERIVATIVE; BIOLOGICAL MARKER; CORTICOSTEROID;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; ASTHMA; CELLULITIS; CHILD; CONTROLLED STUDY; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINUSITIS; TENSION HEADACHE; TOOTH INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; UNITED STATES; URINE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANDROSTADIENES; ASTHMA; BIOLOGICAL MARKERS; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; LUNG; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 83755196759     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-160     Document Type: Article

References (28)

1. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000, 16:802-807. 10.1183/09031936.00.16580200, 11153575.
2. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004, 114:40-47. 10.1016/j.jaci.2004.04.042, 15241342.
3. Haughney J, Barnes G, Partridge M, Cleland J. The Living and Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J 2004, 13:28-35. 10.1016/j.pcrj.2003.11.007, 16701634.
4. Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, Ortega H. Assessment of asthma control in primary care. Curr Med Res Opin 2009, 25:2523-2531. 10.1185/03007990903218655, 19708765.
5. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, Simons FE, Weiss ST, Wenzel SE, Borish L, Bleecker ER, . TENOR Study Group Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009, 124:895-902. 10.1016/j.jaci.2009.07.035, 19811812, TENOR Study Group.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. , http://www.ginasthma.com
7. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010, 10:1. 10.1186/1471-2466-10-1, 2822814, 20051135.
8. Smith LA, Bokhour B, Hohman KH, Miroshnik I, Kleinman KP, Cohn E, Cortés DE, Galbraith A, Rand C, Lieu TA. Modifiable risk factors for suboptimal control and controller medication underuse among children with asthma. Pediatrics 2008, 122:760-769. 10.1542/peds.2007-2750, 18829799.
9. Stanford RH, Gilsenan AW, Ziemiecki R, Zhou X, Lincourt WR, Ortega H. Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma 2010, 47:257-262. 10.3109/02770900903584019, 20210612.
10. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, Ownby DR, Johnson CC. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004, 114:1288-1293. 10.1016/j.jaci.2004.09.028, 15577825.
11. van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, Lammers J-WJ. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010, 65:1531-1535. 10.1111/j.1398-9995.2010.02414.x, 20560909.
12. Biggadike K, Bledsoe RK, Hassell AM, Kirk BE, McLay IM, Shewchuk LM, Stewart EL. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008, 51:3349-3352. 10.1021/jm800279t, 18522385.
13. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007, 293:L660-L667. 10.1152/ajplung.00108.2007, 17575011.
14. Bateman ED, Bleecker ER, Busse W, Lötvall J, Woodcock A, Forth R, Medley H, Jacques L, Haumann B. Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy. Eur Respir J 2010, 36(Suppl 54):204s.
15. Bleecker ER, Bateman ED, Busse W, Lötvall J, Woodcock A, Tomkins S, House K, Jacques L, Haumann B. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010, 36(Suppl 54):204s.
16. Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2011, doi:10.1136/thoraxjnl-2011-200308.
17. National Institutes of Health (NIH) Guidelines for the diagnosis and management of asthma - Expert panel report 3. 2007, U.S. Department of health and human services, Bethesda, MD. NIH publication No. 07-4051, National Institutes of Health (NIH).
18. Masoli M, Weatherall M, Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology 2005, 10:183-8. 10.1111/j.1440-1843.2005.00688.x, 15823183.
19. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Chest 2003, 124:1584-93. 10.1378/chest.124.4.1584, 14555594.
20. Phillips K, Oborne J, Lewis S, Harrison TW, Tattersfield AE. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004, 59:26-30. 10.1136/thx.2003.015297, 1758859, 14694242.
21. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000, 343:332-336. 10.1056/NEJM200008033430504, 10922423.
22. Stempel DA, Roberts CS, Stanford RH. Treatment patterns in the months prior to and after asthma-related emergency department visit. Chest 2004, 126:75-80. 10.1378/chest.126.1.75, 15249445.
23. McLaughlin J, Navaratnam P, Urdaneta E, Friedman H. Patient adherence in adolescent/young adult mild asthma patients treated with inhaled corticosteroids. Proceedings of the Paediatric Academic Society Annual Meeting 1-4 May 2010 E-PAS20101476.251.
24. Woodcock A, Bleecker ER, Bateman ED, Bleecker ER, Lötvall J, Snowise NG, Forth R, Jacques L, Haumann B. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates once-daily efficacy in asthma when dosed in the evening. Eur Respir J 2010, 36(Suppl 54):205s.
25. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997, 100:771-774. 10.1016/S0091-6749(97)70272-0, 9438485.
26. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001, 17:1083-88. 10.1183/09031936.01.00099701, 11491148.
27. Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001, 86:36-43. 10.1016/S1081-1206(10)62353-8, 11206236.
28. Jones AH, Langdon CG, Lee PS, Lingham SA, Nankani JP, Follows RM, Tollemar U, Richardson PD. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994, 88:293-299. 10.1016/0954-6111(94)90059-0, 8036292.